If you have been reading about reverse-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Adolescents experiencing gender dysphoria may opt to undergo puberty-suppressing hormone therapy at the onset of puberty. The Standards of Care set forth by WPATH recommend individuals pursuing puberty-suppressing hormone therapy wait until at least experiencing Tanner Stage 2 pubertal development. Tanner Stage 2 is defined by the appearance of scant pubic hair, breast bud development, and/or slight testicular growth. WPATH classifies puberty-suppressing hormone therapy as a "fully reversible" intervention. Delaying puberty allows individuals more time to explore their gender identity before deciding on more permanent interventions and prevents the physical changes associated with puberty. The preferred puberty-suppressing agent for both individuals assigned male at birth and individuals assigned female at birth is a GnRH Analogue. This approach temporarily shuts down the Hypothalamic-Pituitary-Gonadal (HPG) Axis, which is responsible for the production of hormones (estrogen, testosterone) that cause the development of secondary sexual characteristics in puberty. According to a study by JAMA Pediatrics published in January 2025, less than 0.1% of adolescents covered by private medical insurance in the US take gender-affirming medication to treat gender dysphoria.
== Mode of action == When the isopeptag is bound to a target protein, it spontaneously binds its binding partner through an isopeptide bond, an amide bond formed autocatalytically. The reaction is robust and occurs at various temperatures from 4-37 °C, a pH range of 5–8, and in the presence of commonly used detergents. Also, the reaction is independent of the redox state of the environment and can occur equally well in both reducing and oxidizing conditions.
== History == The ridge was named in 1907 by Mary Schäffer, the same year that Jasper National Park was established. In her book, "A Hunter of Peace," Mary wrote: "A short distance beyond the rock-slide and on the river's right, begins a low, rocky ridge, which for length and unadulterated ugliness cannot be beaten. We trailed it for a day and a half and then named it The Endless Chain, well named too, for on reaching the Athabasca shores, we found that it still stretched on in an unbroken line for miles down the river." The toponym was officially adopted in 1947 by the Geographical Names Board of Canada.
The Kuril Islands or Kurile Islands are a volcanic archipelago administered as part of Sakhalin Oblast in the Russian Far East. The islands stretch approximately 1,300 km (810 mi) northeast from Hokkaido in Japan to Kamchatka Peninsula in Russia, separating the Sea of Okhotsk from the north Pacific Ocean. There are 56 islands and many minor islets. The Kuril Islands consist of the Greater Kuril Chain and, at the southwest end, the parallel Lesser Kuril Chain. The group termed the 'South Kurils' consists of those of the Lesser Kuril Chain together with Kunashir and Iturup in the Greater Kuril Chain. The Vries Strait between Iturup and Urup forms the Miyabe Line dividing the North and South Kurils. The Kuril Islands cover an area of around 10,503.2 square kilometres (4,055.3 sq mi), with a population of roughly 20,000. The islands have been under Russian administration since their 1945 invasion by the Soviet Union near the end of World War II. Japan claims the four southernmost islands, including two of the three largest (Iturup and Kunashir), as part of its territory, as well as Shikotan and the unpopulated Habomai islets, which has led to the ongoing Kuril Islands dispute. The disputed islands are known in Japan as the country's "Northern Territories".
Sources: en.wikipedia.org
Crustacean hyperglycaemic hormone (CHH). CHH is primarily involved in blood sugar regulation, but also plays a role in the control of moulting and reproduction. Moult-inhibiting hormone (MIH). MIH inhibits Y-organs where moulting hormone (ecdysteroid) is secreted. A moulting cycle is initiated when MIH secretion diminishes or stops. Gonad-inhibiting hormone (GIH), also known as vitellogenesis-inhibiting hormone (VIH) because of its role in inhibiting vitellogenesis in female animals. Mandibular organ-inhibiting hormone (MOIH). MOIH represses the synthesis of methyl farnesoate, the precursor of insect juvenile hormone III in the mandibular organ. Ion transport peptide (ITP) from locust. ITP stimulates salt and water reabsorption and inhibits acid secretion in the ileum of the locust. Caenorhabditis elegans uncharacterised protein ZC168.2. These neurohormones are peptides of 70 to 80 amino acid residues which are processed from larger precursors. They contain six conserved cysteines that are involved in disulfide bonds.
=== Antibiotic-associated diarrhea === Evidence supports the use of S. boulardii for the prevention of antibiotic-associated diarrhea (AAD) in both adults and children. The efficacy of probiotics in preventing AAD appears to depend on the specific strain used and the administered dose. A 2015 meta-analysis of 21 randomized controlled trials involving 4,780 participants found that S. boulardii significantly reduced the risk of AAD in adults and children. High-dose probiotics, including S. boulardii and Lactobacillus rhamnosus (more than 5 billion colony-forming units per day), were reported to be moderately effective in preventing AAD in children and may also reduce the duration of diarrhea, without serious adverse effects.
==== Transformation of kerogen into fossil fuels ==== Kerogen formation continued to a depth of about 1 km from the Earth's surface where temperatures may reach around 50 °C. Kerogen formation represents a halfway point between organic matter and fossil fuels: kerogen can be exposed to oxygen, oxidize and thus be lost, or it could be buried deeper inside the Earth's crust and be subjected to conditions which allow it to slowly transform into fossil fuels like petroleum. The latter happened through catagenesis in which the reactions were mostly radical rearrangements of kerogen. These reactions took thousands to millions of years, and no external reactants were involved. Due to the radical nature of these reactions, kerogen reacted towards two classes of products: those with low H/C ratio (anthracene or products similar to it) and those with high H/C ratio (methane or products similar to it); i.e., carbon-rich or hydrogen-rich products. Because catagenesis was closed off from external reactants, the resulting composition of the fuel mixture was dependent on the composition of the kerogen via reaction stoichiometry. Three types of kerogen exist: type I (algal), II (liptinic) and III (humic), which were formed mainly from algae, plankton and woody plants (this term includes trees, shrubs and lianas) respectively.
Posttranslational modifications, especially site-specific phosphorylation mediated either by upstream kinases or by intramolecular autophosphorylation, have been demonstrated to reversibly modulate CK1δ kinase activity. Several residues within the C-terminal regulatory domain of CK1δ were identified as targets for autophosphorylation, including Ser-318, Thr-323, Ser-328, Thr-329, Ser-331, and Thr-337. Upon autophosphorylation sequence motifs within the C-terminal domain are generated, which are able to block the catalytic center of the kinase by acting as a pseudosubstrate. Regulatory function of the C-terminal domain has furthermore been confirmed by the observation that kinase activity is increased after proteolytic cleavage of this domain. Besides autophosphorylation, site-specific phosphorylation by other cellular kinases has been demonstrated to regulate kinase activity. So far, C-terminal phosphorylation of CK1δ by upstream kinases has been confirmed for protein kinase A (PKA), protein kinase B (Akt), cyclin-dependent kinase 2/cyclin E (CDK2/E) and cyclin-dependent kinase 5/p35 (CDK5/p35), CDC-like kinase 2 (CLK2), protein kinase C α (PKCα), and checkpoint kinase 1 (Chk1). For several phosphorylation events also effects on kinase function have been described. For residue Ser-370, which can be phosphorylated at least by PKA, Akt, CLK2, PKCα and Chk1, major regulatory function has been demonstrated.
=== Canada, United States, Mexico === Ractopamine use as a feed additive is authorized in the United States, Canada, and Mexico. In the US, ractopamine is allowed to be used at a feed concentration of 5–20 mg/kg feed for finishing pigs and in dosages of 5–10 mg/kg feed for finishing pigs heavier than 109 kg. The maximum residue limit for ractopamine for meat in the US is 50 parts per billion (ppb), or five times the standard set by the Codex Alimentarius. Ractopamine was approved by the FDA in 1999 for use in swine, in 2003 for use in cattle, and in 2008 for use in turkeys. In 2015, the USDA approved of a new label, "No ractopamine — a beta-agonist growth promotant" to be used. The Canadian Food Inspection Agency (CFIA) maintains the Canadian Ractopamine-Free Pork Certification Program (CRFPCP) so that Canadian exports to Asian countries are not disallowed by their authorities. Hundreds of commercial feed facilities, including some from overseas, are enrolled in the CRFPCP, a programme that is essentially based on self-certification and backed up by a randomized testing policy. Currently, the label for USDA organic means no synthetic compounds can be used other than those on the list of allowed synthetics; therefore, ractopamine would not be allowed in certified organic production.
Sources: en.wikipedia.org
== Biosynthesis and industrial route == In terms of its biosynthesis, it is formed by the degradation of dihydrouracil and carnosine. β-Alanine ethyl ester is the ethyl ester which hydrolyses within the body to form β-alanine. It is produced industrially by the reaction of ammonia with β-propiolactone. Sources for β-alanine includes pyrimidine catabolism of cytosine and uracil.
=== Halide analysis === The silver cation, Ag+, reacts quickly with halide sources to produce the insoluble silver halide. This reaction is used in analytical chemistry to confirm the presence of chloride, bromide, or iodide. The same reaction was used on steamships in order to determine whether or not boiler feedwater had been contaminated with seawater. It is still used to determine moisture on formerly dry cargo as a result of condensation from humid air, or from seawater leaking through the hull.
To better compete with more diversified manufacturers, in 1955 Whirlpool acquired Seeger Refrigerator Company and RCA's air conditioner and cooking range lines. The company changed its name to Whirlpool-Seeger Corporation and began using the RCA-Whirlpool brand name. Whirlpool acquired International Harvester Company's refrigeration plant in Evansville, Indiana, in 1955. In 1956, a 100-acre (0.40 km2) administrative center was opened in Benton Harbor, Michigan. In 1957, the RCA Whirlpool Miracle Kitchen was introduced with an estimated 15 million television viewers. The company changed its name back to Whirlpool Corporation and brought in Robert Elton Brooker as president. At the 1959 American National Exhibition at Sokolniki Park, Moscow, Brooker presided over the Whirlpool kitchen. The Whirlpool kitchen inspired the Kitchen Debate between then Vice President Richard Nixon and Soviet Premier Nikita Khrushchev.
Sir Frederick Grant Banting (; November 14, 1891 – February 21, 1941) was a Canadian pharmacologist, orthopedist, and field surgeon. For his co-discovery of insulin and its therapeutic potential, Banting was awarded the Nobel Prize in Physiology or Medicine with John Macleod. Banting and his student, Charles Best, isolated insulin at the University of Toronto in the lab of Scottish physiologist John Macleod. When he and Macleod received the 1923 Nobel Prize in Physiology or Medicine, Banting shared the honours and award money with Best. That same year, the Government of Canada granted Banting a lifetime annuity to continue his work. He is the youngest Nobel laureate for Physiology/Medicine, at 32.
=== Levels === Prior to puberty in humans, DHEA and DHEA-S levels elevate upon differentiation of the zona reticularis of the adrenal cortex. Peak levels of DHEA and DHEA-S are observed around age 20, which is followed by an age-dependent decline throughout life eventually back to prepubertal concentrations. Plasma levels of DHEA in adult men are 10 to 25 nM, in premenopausal women are 5 to 30 nM, and in postmenopausal women are 2 to 20 nM. Conversely, DHEA-S levels are an order of magnitude higher at 1–10 μM. Levels of DHEA and DHEA-S decline to the lower nanomolar and micromolar ranges in men and women aged 60 to 80 years. DHEA levels are as follows:
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.